Midday Report: SpringWorks (SWTX) Shares Up on August 4

Equities Staff  |

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has risen $2.2 (7.09%) and is currently sitting at $32.65, as of 12:08:35 est on August 4.

221,747 shares exchanged hands.

The Company has increased 4.20% over the last 5 days and shares advanced 17.04% over the last 30 days.

SpringWorks anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on SpringWorks visit the company profile.

About SpringWorks Therapeutics Inc

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.

To get more information on SpringWorks Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: SpringWorks Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content